Pub Date : 2024-12-26DOI: 10.1021/acsinfecdis.4c0096410.1021/acsinfecdis.4c00964
Gaofeng Liang*, Haojie Wang, Hao Shi, Mengxi Zhu, Junling An, Yijun Qi, Jingxia Du, Yan Li and Shegan Gao*,
{"title":"Correction to “Porphyromonas gingivalis Promotes the Proliferation and Migration of Esophageal Squamous Cell Carcinoma through the miR-194/GRHL3/PTEN/Akt Axis”","authors":"Gaofeng Liang*, Haojie Wang, Hao Shi, Mengxi Zhu, Junling An, Yijun Qi, Jingxia Du, Yan Li and Shegan Gao*, ","doi":"10.1021/acsinfecdis.4c0096410.1021/acsinfecdis.4c00964","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00964https://doi.org/10.1021/acsinfecdis.4c00964","url":null,"abstract":"","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"262–263 262–263"},"PeriodicalIF":4.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143086304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-23DOI: 10.1021/acsinfecdis.4c0081010.1021/acsinfecdis.4c00810
Jeremy Goodyear, Matthew Diamandas, Ryan Moreira and Scott D. Taylor*,
The calcium-dependent antibiotics (CDAs) are a group of seven closely related membrane-active cyclic lipopeptide antibiotics (cLPAs) first isolated in the early 1980s from the fermentation broth of Streptomyces coelicolor. Their target was unknown, and the mechanism of action is uncertain. Herein, we report new routes for the synthesis of CDA4b and its analogues, explore the structure–activity relationships at its lipid tail and at positions 3, 9, and 11, and determine the CDAs’ lipid target. A CDA4b analogue in which the epoxide group in CDA’s 6-carbon lipid was replaced with a cyclopropyl group was 4-fold more active than CDA4b which suggests that the epoxide group is not acting as an electrophile to form a covalent bond with CDA4b’s target. The activity of this cyclopropyl analogue was significantly increased by extending the length of the lipid to 10 carbons. Studies with analogues in which d-HOAsn9 is replaced with d-Asn9 or d-Ser9 reveal that the hydroxy group of the d-HOAsn9 residue is not crucial for CDAs’ activity, while the amide moiety is important for activity. The l-Trp residue at position 11 could be replaced with l-kynurenine (l-Kyn) without significant loss of activity, while replacing the d-Trp residue at position 3 with d-Kyn resulted in a significant loss of activity. MIC values determined in the presence and absence of exogenous phospholipids and fluorescence spectroscopy studies using natural CDAs and CDA4b analogues containing Kyn and model membranes revealed that the CDAs’ primary lipid target is cardiolipin, a target that is unique among the broader class of known calcium-dependent antibiotics.
{"title":"The Calcium-Dependent Antibiotics: Structure–Activity Relationships and Determination of Their Lipid Target","authors":"Jeremy Goodyear, Matthew Diamandas, Ryan Moreira and Scott D. Taylor*, ","doi":"10.1021/acsinfecdis.4c0081010.1021/acsinfecdis.4c00810","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00810https://doi.org/10.1021/acsinfecdis.4c00810","url":null,"abstract":"<p >The calcium-dependent antibiotics (CDAs) are a group of seven closely related membrane-active cyclic lipopeptide antibiotics (cLPAs) first isolated in the early 1980s from the fermentation broth of <i>Streptomyces coelicolor</i>. Their target was unknown, and the mechanism of action is uncertain. Herein, we report new routes for the synthesis of CDA4b and its analogues, explore the structure–activity relationships at its lipid tail and at positions 3, 9, and 11, and determine the CDAs’ lipid target. A CDA4b analogue in which the epoxide group in CDA’s 6-carbon lipid was replaced with a cyclopropyl group was 4-fold more active than CDA4b which suggests that the epoxide group is not acting as an electrophile to form a covalent bond with CDA4b’s target. The activity of this cyclopropyl analogue was significantly increased by extending the length of the lipid to 10 carbons. Studies with analogues in which <span>d</span>-HOAsn9 is replaced with <span>d</span>-Asn9 or <span>d</span>-Ser9 reveal that the hydroxy group of the <span>d</span>-HOAsn9 residue is not crucial for CDAs’ activity, while the amide moiety is important for activity. The <span>l</span>-Trp residue at position 11 could be replaced with <span>l</span>-kynurenine (<span>l</span>-Kyn) without significant loss of activity, while replacing the <span>d</span>-Trp residue at position 3 with <span>d</span>-Kyn resulted in a significant loss of activity. MIC values determined in the presence and absence of exogenous phospholipids and fluorescence spectroscopy studies using natural CDAs and CDA4b analogues containing Kyn and model membranes revealed that the CDAs’ primary lipid target is cardiolipin, a target that is unique among the broader class of known calcium-dependent antibiotics.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"226–237 226–237"},"PeriodicalIF":4.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143086099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-23DOI: 10.1021/acsinfecdis.4c0060610.1021/acsinfecdis.4c00606
Hugo Fernando Georges Roux, Franck Touret, Pascal Rathelot, Pietro Sciò, Antonio Coluccia, Patrice Vanelle* and Manon Roche*,
Enterovirus (EV) is a genus that includes a large diversity of viruses spread around the world. They are the main cause of numerous diseases with seasonal clusters, like hand-foot-mouth disease (HFMD). A vaccine is marketed in China for the prevention of HFMD caused by EV-A71. Despite the need, no antiviral is marketed to date. Therefore, several compounds have been currently evaluated to inhibit non-polio Enterovirus (NPEV), namely direct antiviral agents and host target inhibitor. We propose to make a review of the latest molecules evaluated as NPEV inhibitors and to summarize structure–activity relationships between these inhibitors and their target. We provide access to all recent information on Enterovirus inhibitors, regardless of the species, to facilitate the design of future broad-spectrum drugs.
{"title":"Non-Polio Enterovirus Inhibitors: Scaffolds, Targets, and Potency─What’s New?","authors":"Hugo Fernando Georges Roux, Franck Touret, Pascal Rathelot, Pietro Sciò, Antonio Coluccia, Patrice Vanelle* and Manon Roche*, ","doi":"10.1021/acsinfecdis.4c0060610.1021/acsinfecdis.4c00606","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00606https://doi.org/10.1021/acsinfecdis.4c00606","url":null,"abstract":"<p >Enterovirus (EV) is a genus that includes a large diversity of viruses spread around the world. They are the main cause of numerous diseases with seasonal clusters, like hand-foot-mouth disease (HFMD). A vaccine is marketed in China for the prevention of HFMD caused by EV-A71. Despite the need, no antiviral is marketed to date. Therefore, several compounds have been currently evaluated to inhibit non-polio Enterovirus (NPEV), namely direct antiviral agents and host target inhibitor. We propose to make a review of the latest molecules evaluated as NPEV inhibitors and to summarize structure–activity relationships between these inhibitors and their target. We provide access to all recent information on Enterovirus inhibitors, regardless of the species, to facilitate the design of future broad-spectrum drugs.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"21–46 21–46"},"PeriodicalIF":4.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143085642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.1021/acsinfecdis.4c0083210.1021/acsinfecdis.4c00832
Jordan L. Pederick, Bethiney C. Vandborg, Amir George, Hannah Bovermann, Jeffrey M. Boyd, Joel S. Freundlich and John B. Bruning*,
The pathway of bacterial cysteine biosynthesis is gaining traction for the development of antibiotic adjuvants. Bacterial cysteine biosynthesis is generally facilitated by two enzymes possessing O-acetyl-l-serine sulfhydrylases (OASS), CysK and CysM. In Staphylococcus aureus, there exists a single OASS homologue, SaCysK. Knockout of SaCysK was found to increase sensitivity to oxidative stress, making it a relevant target for inhibitor development. SaCysK also forms two functional complexes via interaction with the preceding enzyme in the pathway serine acetyltransferase (CysE) or the transcriptional regulator of cysteine metabolism (CymR). These interactions occur through insertion of a C-terminal peptide of CysE or CymR into the active site of SaCysK, inhibiting OASS activity, and therefore represent an excellent starting point for developing SaCysK inhibitors. Here, we detail the characterization of CysE and CymR-derived C-terminal peptides as inhibitors of SaCysK. Using a combination of X-ray crystallography, surface plasmon resonance, and enzyme inhibition assays, it was determined that the CymR-derived decapeptide forms extensive interactions with SaCysK and acts as a potent inhibitor (KD = 25 nM; IC50 = 180 nM), making it a promising lead for the development of SaCysK inhibitors. To understand the determinants of this high-affinity interaction, the structure–activity relationships of 16 rationally designed peptides were also investigated. This identified that the C-terminal pentapeptide of CymR facilitates the high-affinity interaction with SaCysK and that subtle structural modification of the pentapeptide is possible without impacting potency. Ultimately, this work identified CymR pentapeptides as a promising scaffold for the development of antibiotic adjuvants targeting SaCysK.
{"title":"Identification of Cysteine Metabolism Regulator (CymR)-Derived Pentapeptides as Nanomolar Inhibitors of Staphylococcus aureus O-Acetyl-l-serine Sulfhydrylase (CysK)","authors":"Jordan L. Pederick, Bethiney C. Vandborg, Amir George, Hannah Bovermann, Jeffrey M. Boyd, Joel S. Freundlich and John B. Bruning*, ","doi":"10.1021/acsinfecdis.4c0083210.1021/acsinfecdis.4c00832","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00832https://doi.org/10.1021/acsinfecdis.4c00832","url":null,"abstract":"<p >The pathway of bacterial cysteine biosynthesis is gaining traction for the development of antibiotic adjuvants. Bacterial cysteine biosynthesis is generally facilitated by two enzymes possessing <i>O</i>-acetyl-<span>l</span>-serine sulfhydrylases (OASS), CysK and CysM. In <i>Staphylococcus aureus</i>, there exists a single OASS homologue, <i>Sa</i>CysK. Knockout of <i>Sa</i>CysK was found to increase sensitivity to oxidative stress, making it a relevant target for inhibitor development. <i>Sa</i>CysK also forms two functional complexes via interaction with the preceding enzyme in the pathway serine acetyltransferase (CysE) or the transcriptional regulator of cysteine metabolism (CymR). These interactions occur through insertion of a C-terminal peptide of CysE or CymR into the active site of <i>Sa</i>CysK, inhibiting OASS activity, and therefore represent an excellent starting point for developing <i>Sa</i>CysK inhibitors. Here, we detail the characterization of CysE and CymR-derived C-terminal peptides as inhibitors of <i>Sa</i>CysK. Using a combination of X-ray crystallography, surface plasmon resonance, and enzyme inhibition assays, it was determined that the CymR-derived decapeptide forms extensive interactions with <i>Sa</i>CysK and acts as a potent inhibitor (<i>K</i><sub>D</sub> = 25 nM; IC<sub>50</sub> = 180 nM), making it a promising lead for the development of <i>Sa</i>CysK inhibitors. To understand the determinants of this high-affinity interaction, the structure–activity relationships of 16 rationally designed peptides were also investigated. This identified that the C-terminal pentapeptide of CymR facilitates the high-affinity interaction with <i>Sa</i>CysK and that subtle structural modification of the pentapeptide is possible without impacting potency. Ultimately, this work identified CymR pentapeptides as a promising scaffold for the development of antibiotic adjuvants targeting <i>Sa</i>CysK.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"238–248 238–248"},"PeriodicalIF":4.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143085902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.1021/acsinfecdis.4c0086010.1021/acsinfecdis.4c00860
Navjot Kaur, and , Mrinmoy De*,
Bacterial resistance, accelerated by the misuse of antibiotics, remains a critical concern for public health, promoting an ongoing exploration for cost-effective and safe antibacterial agents. Recently, there has been significant focus on various nanomaterials for the development of alternative antibiotics. Among these, molybdenum disulfide (MoS2) has gained attention due to its unique chemical, physical, and electronic properties, as well as its semiconducting nature, biocompatibility, and colloidal stability, positioning it as a promising candidate for biomedical research. The impact of the shape and size of MoS2 nanomaterials on the antibacterial activity remains largely unexplored. In this study, we investigated the effect of the shape and size of MoS2 nanomaterials, such as quantum dots, nanoflowers, and nanosheets, on antimicrobial and anti-biofilm activity. As we had established earlier, functionalization with positively charged thiol ligands can enhance colloidal stability, biocompatibility, and antibacterial efficacy; we functionalized all targeted nanomaterials. Our results revealed that functionalized MoS2 quantum dots (F-MQDs) exhibited superior activity compared to functionalized MoS2 nanoflowers (F-MNFs) and functionalized MoS2 nanosheets (F-MNSs) against Staphylococcus aureus (SA), both drug-resistant (methicillin) and nonresistant strains. We observed very low minimum inhibitory concentration (MIC, 30 ng/mL) for F-MQDs. The observed trend in antibacterial efficacy was as follows: F-MQDs > F-MNFs ≥ F-MNSs. We explored the relevant mechanism related to the antibacterial activity where the balance between membrane depolarization and internalization plays the determining role. Furthermore, F-MQDs show enhanced anti-biofilm activity compared to F-MNFs and F-MNSs against mature MRSA biofilms. Due to the superior antibacterial and anti-biofilm activity of F-MQDs, we extended their application to wound healing. This study will help us to develop other appropriate surface modified nanomaterials for antibacterial and anti-biofilm activity for further applications such as antibacterial coatings, water disinfection, and wound healing.
{"title":"Shape and Size Dependent Antimicrobial and Anti-biofilm Properties of Functionalized MoS2","authors":"Navjot Kaur, and , Mrinmoy De*, ","doi":"10.1021/acsinfecdis.4c0086010.1021/acsinfecdis.4c00860","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00860https://doi.org/10.1021/acsinfecdis.4c00860","url":null,"abstract":"<p >Bacterial resistance, accelerated by the misuse of antibiotics, remains a critical concern for public health, promoting an ongoing exploration for cost-effective and safe antibacterial agents. Recently, there has been significant focus on various nanomaterials for the development of alternative antibiotics. Among these, molybdenum disulfide (MoS<sub>2</sub>) has gained attention due to its unique chemical, physical, and electronic properties, as well as its semiconducting nature, biocompatibility, and colloidal stability, positioning it as a promising candidate for biomedical research. The impact of the shape and size of MoS<sub>2</sub> nanomaterials on the antibacterial activity remains largely unexplored. In this study, we investigated the effect of the shape and size of MoS<sub>2</sub> nanomaterials, such as quantum dots, nanoflowers, and nanosheets, on antimicrobial and anti-biofilm activity. As we had established earlier, functionalization with positively charged thiol ligands can enhance colloidal stability, biocompatibility, and antibacterial efficacy; we functionalized all targeted nanomaterials. Our results revealed that functionalized MoS<sub>2</sub> quantum dots (F-MQDs) exhibited superior activity compared to functionalized MoS<sub>2</sub> nanoflowers (F-MNFs) and functionalized MoS<sub>2</sub> nanosheets (F-MNSs) against <i>Staphylococcus aureus</i> (SA), both drug-resistant (methicillin) and nonresistant strains. We observed very low minimum inhibitory concentration (MIC, 30 ng/mL) for F-MQDs. The observed trend in antibacterial efficacy was as follows: F-MQDs > F-MNFs ≥ F-MNSs. We explored the relevant mechanism related to the antibacterial activity where the balance between membrane depolarization and internalization plays the determining role. Furthermore, F-MQDs show enhanced anti-biofilm activity compared to F-MNFs and F-MNSs against mature MRSA biofilms. Due to the superior antibacterial and anti-biofilm activity of F-MQDs, we extended their application to wound healing. This study will help us to develop other appropriate surface modified nanomaterials for antibacterial and anti-biofilm activity for further applications such as antibacterial coatings, water disinfection, and wound healing.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"249–261 249–261"},"PeriodicalIF":4.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143085737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-19DOI: 10.1021/acsinfecdis.4c0098210.1021/acsinfecdis.4c00982
Maneesh Paul-Satyaseela*,
The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India. It is a novel beta-lactamase inhibitor invented by scientists at Orchid Pharma in Chennai, India, and has garnered international attention for its potential to address antimicrobial resistance. It became the first new chemical entity invented in India, clinically developed by Allecra Therapeutics GmbH, to be approved by the U.S. Food & Drug Administration, with additional approvals from the European Medical Agency, the U.K.’s Medicine & Healthcare Products Regulatory Agency, and the Drug Controller General of India.
{"title":"Invention of Enmetazobactam: An Indian Triumph in Antimicrobial Drug Discovery","authors":"Maneesh Paul-Satyaseela*, ","doi":"10.1021/acsinfecdis.4c0098210.1021/acsinfecdis.4c00982","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00982https://doi.org/10.1021/acsinfecdis.4c00982","url":null,"abstract":"<p >The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India. It is a novel beta-lactamase inhibitor invented by scientists at Orchid Pharma in Chennai, India, and has garnered international attention for its potential to address antimicrobial resistance. It became the first new chemical entity invented in India, clinically developed by Allecra Therapeutics GmbH, to be approved by the U.S. Food & Drug Administration, with additional approvals from the European Medical Agency, the U.K.’s Medicine & Healthcare Products Regulatory Agency, and the Drug Controller General of India.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"1–3 1–3"},"PeriodicalIF":4.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143085052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-18DOI: 10.1021/acsinfecdis.4c0051310.1021/acsinfecdis.4c00513
Urja Joshi*, Sumedha Shah, Sharad Gupta, Linz-Buoy George and Hyacinth Highland,
Falciparum malaria relies extensively on cell-to-cell communication, and earlier research on the function of exosomal proteins derived from infected red blood cells (iRBCs) has been classified into numerous important roles. In this study, the exosomes were derived from Pf3D7-iRBCs cultured in vitro during synchronized trophozoite stages. The isolated exosomes were assessed using NTA, FE-SEM, and flow cytometry. Our study reported heterogeneous populations of exosomes during the infection. Additionally, label-free quantification based on LC/MS-MS for protein profiling revealed the presence of both parasitic and host (RBC) proteins; out of a total of 124 proteins detected, 20 Pf3D7 proteins and 80 RBC proteins were identified. Exosomal RBC protein expression is different in cRBCs-Exo and iRBCs-Exo, which shows how the parasite and RBCs interact with each other. Functional classification reported that the majority of these Pf3D7 proteins are uncharacterized with unknown functions, few of which are involved in biological processes such as regulation of complement activation, response to external stimuli, immune system-mediated signaling pathway, protein processing, etc. Hence, studying these exosomal proteins and comparing them to previous research has helped us understand how exosomes help cells to communicate in malaria. It may also reveal new potential biomarkers for diagnostic methods or therapies for malaria.
{"title":"Evaluation of Exosomal Proteins as Potential Biomarkers from RBC Stages of Plasmodium falciparum 3D7","authors":"Urja Joshi*, Sumedha Shah, Sharad Gupta, Linz-Buoy George and Hyacinth Highland, ","doi":"10.1021/acsinfecdis.4c0051310.1021/acsinfecdis.4c00513","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00513https://doi.org/10.1021/acsinfecdis.4c00513","url":null,"abstract":"<p >Falciparum malaria relies extensively on cell-to-cell communication, and earlier research on the function of exosomal proteins derived from infected red blood cells (iRBCs) has been classified into numerous important roles. In this study, the exosomes were derived from <i>Pf3D7</i>-iRBCs cultured in vitro during synchronized trophozoite stages. The isolated exosomes were assessed using NTA, FE-SEM, and flow cytometry. Our study reported heterogeneous populations of exosomes during the infection. Additionally, label-free quantification based on LC/MS-MS for protein profiling revealed the presence of both parasitic and host (RBC) proteins; out of a total of 124 proteins detected, 20 <i>Pf3D7</i> proteins and 80 RBC proteins were identified. Exosomal RBC protein expression is different in cRBCs-Exo and iRBCs-Exo, which shows how the parasite and RBCs interact with each other. Functional classification reported that the majority of these <i>Pf3D7</i> proteins are uncharacterized with unknown functions, few of which are involved in biological processes such as regulation of complement activation, response to external stimuli, immune system-mediated signaling pathway, protein processing, etc. Hence, studying these exosomal proteins and comparing them to previous research has helped us understand how exosomes help cells to communicate in malaria. It may also reveal new potential biomarkers for diagnostic methods or therapies for malaria.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"164–180 164–180"},"PeriodicalIF":4.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143085452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-17DOI: 10.1021/acsinfecdis.4c0077310.1021/acsinfecdis.4c00773
Uttam Ghosh, and , Yftah Tal-Gan*,
Streptococcus oligofermentans, a Gram-positive bacterium found in the oral microbiome, shows promise as an oral probiotic for preventing dental caries. It exhibits a reverse correlation with Streptococcus mutans, a key caries-causing pathogen, likely due to its production of hydrogen peroxide, a process mediated by quorum sensing (QS). In this work, we set out to develop novel lactam-based cyclic analogues of the competence stimulating peptide (CSP) signal utilized by S. oligofermentans for QS activation. To this end, we first conducted a ring position scan, where we determined the best positions within the CSP sequence to use for macrolactamization. We then conducted systematic ring size and bridge position scans to fine-tune the cyclic peptide conformation and identified a cyclic analogue, CSP-cyc(K2E2), with enhanced biological activity, 7-fold more active than the native CSP signal. This analogue also exhibited improved stability toward enzymatic degradation, demonstrating this analogue’s potential utility as a chemical probe to study interspecies interactions between oral microbes and as a potential therapeutic agent. Overall, our lead cyclic analogue could be applied to augment the biotherapeutic potential of S. oligofermentans against S. mutans infections.
{"title":"Designing Highly Potent Side-Chain Lactam-Bridged Cyclic Competence-Stimulating Peptide-Based Quorum-Sensing Modulators in Streptococcus oligofermentans","authors":"Uttam Ghosh, and , Yftah Tal-Gan*, ","doi":"10.1021/acsinfecdis.4c0077310.1021/acsinfecdis.4c00773","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00773https://doi.org/10.1021/acsinfecdis.4c00773","url":null,"abstract":"<p ><i>Streptococcus oligofermentans</i>, a Gram-positive bacterium found in the oral microbiome, shows promise as an oral probiotic for preventing dental caries. It exhibits a reverse correlation with <i>Streptococcus mutans</i>, a key caries-causing pathogen, likely due to its production of hydrogen peroxide, a process mediated by quorum sensing (QS). In this work, we set out to develop novel lactam-based cyclic analogues of the competence stimulating peptide (CSP) signal utilized by <i>S. oligofermentans</i> for QS activation. To this end, we first conducted a ring position scan, where we determined the best positions within the CSP sequence to use for macrolactamization. We then conducted systematic ring size and bridge position scans to fine-tune the cyclic peptide conformation and identified a cyclic analogue, CSP-cyc(K2E2), with enhanced biological activity, 7-fold more active than the native CSP signal. This analogue also exhibited improved stability toward enzymatic degradation, demonstrating this analogue’s potential utility as a chemical probe to study interspecies interactions between oral microbes and as a potential therapeutic agent. Overall, our lead cyclic analogue could be applied to augment the biotherapeutic potential of <i>S. oligofermentans</i> against <i>S. mutans</i> infections.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"197–203 197–203"},"PeriodicalIF":4.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143084632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-16DOI: 10.1021/acsinfecdis.4c0078710.1021/acsinfecdis.4c00787
Michel Nguyen, Lucie Paloque, Jeanne Manaranche, Mickaël Chabbert, Alexandre Hamouy, Marion Laurent, Jean-Michel Augereau, Catherine Claparols, Anne Robert* and Françoise Benoit-Vical*,
The 1,2,4-trioxolane antimalarial drug, OZ439 (artefenomel), exhibits cross-resistance to artemisinins in vitro with similar survival rates of artemisinin-resistant parasites after dihydroartemisinin or OZ439 exposure, suggesting that this drug shares some mechanisms of action with artemisinins. In this way, we investigated the in vitro reductive activation of OZ439 by heme in the presence of dithionite, demonstrating the formation of covalent heme-drug adducts. However, in the presence of the biologically abundant reductant glutathione instead of dithionite, heme-drug adducts were not detected, contrary to artemisinin that efficiently alkylates heme regardless of the reductant used. Conversely, the C-centered radical of OZ439 resulting from heme-mediated activation of the drug reacts with the thiol function of glutathione, thus confirming the ability of this drug to alkylate proteins or other biological targets. So, the difference in the mechanism of action between artemisinin and OZ439 in vivo may rely on the different proportions between heme alkylation and protein alkylation.
{"title":"Reductive Activation of Artefenomel (OZ439) by Fe(II)-Heme, Related to Its Antimalarial Activity","authors":"Michel Nguyen, Lucie Paloque, Jeanne Manaranche, Mickaël Chabbert, Alexandre Hamouy, Marion Laurent, Jean-Michel Augereau, Catherine Claparols, Anne Robert* and Françoise Benoit-Vical*, ","doi":"10.1021/acsinfecdis.4c0078710.1021/acsinfecdis.4c00787","DOIUrl":"https://doi.org/10.1021/acsinfecdis.4c00787https://doi.org/10.1021/acsinfecdis.4c00787","url":null,"abstract":"<p >The 1,2,4-trioxolane antimalarial drug, OZ439 (artefenomel), exhibits cross-resistance to artemisinins <i>in vitro</i> with similar survival rates of artemisinin-resistant parasites after dihydroartemisinin or OZ439 exposure, suggesting that this drug shares some mechanisms of action with artemisinins. In this way, we investigated the <i>in vitro</i> reductive activation of OZ439 by heme in the presence of dithionite, demonstrating the formation of covalent heme-drug adducts. However, in the presence of the biologically abundant reductant glutathione instead of dithionite, heme-drug adducts were not detected, contrary to artemisinin that efficiently alkylates heme regardless of the reductant used. Conversely, the C-centered radical of OZ439 resulting from heme-mediated activation of the drug reacts with the thiol function of glutathione, thus confirming the ability of this drug to alkylate proteins or other biological targets. So, the difference in the mechanism of action between artemisinin and OZ439 <i>in vivo</i> may rely on the different proportions between heme alkylation and protein alkylation.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 1","pages":"216–225 216–225"},"PeriodicalIF":4.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143084729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-13Epub Date: 2024-11-05DOI: 10.1021/acsinfecdis.4c00639
Seoung-Ryoung Choi, Smita Kulkarni, Eusondia Arnett, Larry S Schlesinger, Bradley E Britigan, Prabagaran Narayanasamy
Coinfection of Mycobacterium tuberculosis (Mtb) and human immunodeficiency virus-1 (HIV) is a significant public health concern. Treatment is challenging due to prolonged duration of therapy and drug interactions between antiretroviral therapy (ART) and anti-TB drugs. Noniron gallium meso-tetraphenyl porphyrin (GaTP), a heme mimetic, has shown broad antimicrobial activity. Here, we investigated the efficacy of nanoparticle encapsulating GaTP (GaNP) for the treatment of HIV and Mtb coinfection or single infection in in vitro granuloma structures. GaNP significantly reduced viable Mtb within primary human in vitro granuloma structures infected with Mtb H37Rv-lux and significantly reduced levels of HIV in CD4+ T cells infected with the virus axenically. Similarly, GaNP exhibited significant antimicrobial activity against HIV/Mtb-coinfected granuloma structures created in vitro, which contain the primary immune cells seen in human TB granulomas, including CD4+ T cells and macrophages, as assessed by a luciferase assay for Mtb and p24 ELISA for HIV detection. Furthermore, mechanistic studies revealed that GaTP increases the level of reactive oxygen species and inhibits catalase in Mtb. A significant increase in Mtb nitrate reductase activity was also observed when Mtb was incubated with GaTP and sodium nitrate. Overall, increased oxidative stress and nitrite levels induced by GaTP are consistent with the possibility that GaTP inhibits Mtb aerobic respiration, which leads to incomplete O2 reduction and a shift to respiration using exogenous NO3. These cumulative data continue to support the potential for developing the noniron heme analog GaTP and its nanoparticle GaNP as new therapeutic approaches for the treatment of HIV/Mtb coinfection.
{"title":"Efficacy and Possible Mechanism(s) of Action of Gallium Tetraphenylporphyrin Nanoparticles against HIV-TB Coinfection in an <i>In Vitro</i> Granuloma Structure Model.","authors":"Seoung-Ryoung Choi, Smita Kulkarni, Eusondia Arnett, Larry S Schlesinger, Bradley E Britigan, Prabagaran Narayanasamy","doi":"10.1021/acsinfecdis.4c00639","DOIUrl":"10.1021/acsinfecdis.4c00639","url":null,"abstract":"<p><p>Coinfection of <i>Mycobacterium tuberculosis</i> (Mtb) and human immunodeficiency virus-1 (HIV) is a significant public health concern. Treatment is challenging due to prolonged duration of therapy and drug interactions between antiretroviral therapy (ART) and anti-TB drugs. Noniron gallium <i>meso</i>-tetraphenyl porphyrin (GaTP), a heme mimetic, has shown broad antimicrobial activity. Here, we investigated the efficacy of nanoparticle encapsulating GaTP (GaNP) for the treatment of HIV and Mtb coinfection or single infection in <i>in vitro</i> granuloma structures. GaNP significantly reduced viable Mtb within primary human <i>in vitro</i> granuloma structures infected with Mtb H37Rv-lux and significantly reduced levels of HIV in CD4+ T cells infected with the virus axenically. Similarly, GaNP exhibited significant antimicrobial activity against HIV/Mtb-coinfected granuloma structures created <i>in vitro</i>, which contain the primary immune cells seen in human TB granulomas, including CD4+ T cells and macrophages, as assessed by a luciferase assay for Mtb and p24 ELISA for HIV detection. Furthermore, mechanistic studies revealed that GaTP increases the level of reactive oxygen species and inhibits catalase in Mtb. A significant increase in Mtb nitrate reductase activity was also observed when Mtb was incubated with GaTP and sodium nitrate. Overall, increased oxidative stress and nitrite levels induced by GaTP are consistent with the possibility that GaTP inhibits Mtb aerobic respiration, which leads to incomplete O<sub>2</sub> reduction and a shift to respiration using exogenous NO<sub>3</sub>. These cumulative data continue to support the potential for developing the noniron heme analog GaTP and its nanoparticle GaNP as new therapeutic approaches for the treatment of HIV/Mtb coinfection.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":"4279-4290"},"PeriodicalIF":4.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}